Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mahendra Sanapati

Interventional Pain Medicine Evansville, IN Medical Doctor

NPI 1154325959 CMS profile 566594

1101 Professional Blvd, Ste 100, Evansville, IN 47714

Open in the dashboard

General payments

$30,749

484 records reported · program years 2019–2025

Research payments

$7,550

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$188,054 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mahendra Sanapati of Evansville, IN is reported in the CMS Open Payments database as having received $30,749 across 484 general payments and $7,550 in research payments paid to them. Separately, studies naming them as principal investigator received $188,054 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,773 54
2024 General $2,436 55
2023 General $3,449 55
2022 General $4,128 87
2021 General $3,409 85
2021 Research $800 2
2020 General $2,609 53
2020 Research $5,750 2
2019 General $12,945 95
2019 Research $1,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahendra Sanapati
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Mahendra Sanapati were reported at $1,773. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Mahendra Sanapati Interventional Pain Medicine median Middle half National median
2019 $12,945 $684 $216–$2,079 $163
2020 $2,609 $382 $122–$1,109 $114
2021 $3,409 $552 $167–$1,554 $132
2022 $4,128 $605 $187–$1,924 $149
2023 $3,449 $671 $195–$1,915 $160
2024 $2,436 $684 $206–$1,837 $164
2025 $1,773 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. US WorldMeds, LLC $7,145 10 payments
  2. Nevro Corp. $4,333 92 payments
  3. Medtronic, Inc. $2,957 106 payments
  4. Medtronic USA, Inc. $2,357 65 payments
  5. Spinal Simplicity, LLC $1,876 21 payments
  6. SI-BONE, Inc. $1,653 14 payments
  7. Boston Scientific Corporation $1,485 50 payments
  8. SurGenTec $1,376 1 payment
  9. Medtronic Vascular, Inc. $1,271 10 payments
  10. Flowonix Medical Incorporated $1,181 2 payments
  11. Other $5,114 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,121 440 payments
  2. Travel and Lodging $8,636 37 payments
  3. Consulting Fee $4,930 1 payment
  4. Entertainment $966 1 payment
  5. Education $96 5 payments
Products named General payments · program years 2019–2025
  1. Lucemyra/Lofexidine $7,145 10 payments
  2. Senza Spinal Cord Stimulation System $2,406 23 payments
  3. HA MINUTEMAN G3-R $1,876 21 payments
  4. ION Facet Screw System $1,376 1 payment
  5. ClosureFast $1,242 9 payments
  6. Prometra II $1,181 2 payments
  7. Omnia $1,083 20 payments
  8. SYNCHROMED $1,023 13 payments
  9. Senza $1,005 52 payments
  10. INTELLIS ADAPTIVESTIM $1,004 28 payments
  11. Other $12,699 359 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. US WorldMeds, LLC $5,500 1 payment
  2. Flowonix Medical Incorporated $1,250 2 payments
  3. Nevro Corp. $800 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

5,812

Median for Interventional Pain Management: 1,220

Drug cost

$224,987

Median for Interventional Pain Management: $39,344

Branded share of claims

61%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 59 $86,382
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 2,017 $46,784
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,319 $28,670
Lidocaine Generic 129 $22,904
Gabapentin Generic 543 $6,045
Buprenorphine Generic 24 $5,451
Oxycodone Hcl Generic 301 $4,997
Hydromorphone Hcl Generic 278 $4,352
Pregabalin Generic 154 $3,298
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 16 $2,994

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$298,644

Medicare's payments for the services billed

Medicare patients

801

Average age 66

Services billed

3,973

485 women, 316 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 39%
Diabetes 38%
COPD 27%
Ischemic heart disease 26%
Chronic kidney disease 26%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAVNEOS
  • Amgen Inc. $55
$55 — —
UBRELVY
  • AbbVie, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

489 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record